Reuters logo
BRIEF-CRITICAL OUTCOME TECHNOLOGIES DOSES FIRST PATIENT IN HNSCC ARM OF PHASE 1 TRIAL OF COTI-2
2017年10月11日 / 上午11点18分 / 11 天前

BRIEF-CRITICAL OUTCOME TECHNOLOGIES DOSES FIRST PATIENT IN HNSCC ARM OF PHASE 1 TRIAL OF COTI-2

Oct 11 (Reuters) - Critical Outcome Technologies Inc :

* CRITICAL OUTCOME TECHNOLOGIES ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 TRIAL OF COTI-2 IN HEAD AND NECK SQUAMOUS CELL CARCINOMA

* CRITICAL OUTCOME TECHNOLOGIES - ‍TOP-LINE DATA OF COTI-2 IN HEAD AND NECK SQUAMOUS CELL CARCINOMA ​EXPECTED IN 2018

* CRITICAL OUTCOME TECHNOLOGIES INC - ‍REMAIN ON TRACK TO ANNOUNCE SECONDARY AND EXPLORATORY ENDPOINT DATA OF COTI-2​ BY YEAR-END Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below